Capital One Financial Corp. vs ResMed Inc. — how do they compare? Capital One Financial Corp. trades at $219.35 (market cap $134.45B), while ResMed Inc. trades at $220 (market cap $32.61B). The key difference: Capital One Financial Corp. is far larger — about 4.1× ResMed Inc.'s market cap, and Capital One Financial Corp. pays the higher dividend (1.46%). Which is the better fit depends on your goals.
| COF | RMD | |
|---|---|---|
Market Cap | $134.45B | $32.61B |
Sector | Financials | Health |
52-Week High | $257.94 | $293.73 |
52-Week Low | $176.10 | $182.82 |
Dividend Yield | 1.46% | 1.17% |
Enterprise Value | — | $31.97B |
Signals from Pluang's Aura AI — not financial advice
Capital One Financial (COF) trades at $218.97, up 0.56% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81, while revenue growth accelerated to $53.43B in 2025. The Discover integration is on track, targeting $2.5B in synergies by late 2027, supporting double-digit EPS growth projections.
The outlook is positive, driven by strong card growth, technology advantages, and merger synergies, but risks include integration execution, credit loss provisions, and macroeconomic sensitivity. With a P/E of 12.07 and 63% analyst buy ratings, the stock offers value if Discover benefits materialize as planned.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →